What makes this particularly good news is that the Food and Drug Administration and the World Health Organization approved nisin as safe for human consumption decades ago, says Yvonne Kapila, the study’s principal investigator and professor at the University of Michigan School of Dentistry.
This means that obtaining FDA approval to test nisin’s suggested cancer-fighting properties on patients in a clinical setting won’t take as long as a new therapy that hasn’t been tried yet on people, she says.
Antibacterial agents like nisin alter cell properties in bacteria to render it harmless. However, it’s only recently that scientists began looking to antibacterial agents like nisin to see if they altered properties in other types of cells, such as cancer cells or cells in tumors.
Oral cancer is a leading cause of death worldwide, and oral squamous cell carcinoma accounts for more than 90 percent of oral cancers. However, survival rates for oral cancer haven’t improved in decades, according to the study.
“The poor five-year survival rates for oral cancer underscore the need to find new therapies for oral cancer,” Kapila said. “The use of small antibacterial agents, like nisin, to treat cancer is a new approach that holds great promise. Nisin is a perfect example of this potential because it has been used safely in humans for many years, and now the laboratory studies support its anti-tumor potential.”
The U-M study, which looked at the use of antimicrobials to fight cancerous tumors, suggests nisin, in part, slows cell proliferation or causes cell death through the activation of a protein called CHAC1 in cancer cells, a protein known to influence cell death.
The study is the first to show CHAC1’s new role in promoting cancer cell death under nisin treatment. The findings also suggest that nisin may work by creating pores in the cancer cell membranes that allow an influx of calcium. It’s unclear what role calcium plays in nisin-triggered cell death, but it’s well known that calcium is a key regulator in cell death and survival.
Additionally, the findings suggest that nisin slows or stops tumor growth by interrupting the cell cycle in “bad” cells but not the good cells; thus nisin stops cancer cell proliferation but doesn’t hurt good cells.
The paper, “Nisin, an apoptogenic bacteriocin and food preservative, attenuates HNSCC tumorigenesis via CHAC,” appears this month in the journal Cancer Medicine.
- Yvonne Kapila: www.dent.umich.edu/pom/faculty/links/ykbio
- U-M School Dentistry: http://dent.umich.edu